Last updated: February 24, 2026
What is NDC 70677-0001?
NDC 70677-0001 is a specific formulation of aflibercept, marketed as Eylea. It is an anti-vascular endothelial growth factor (VEGF) agent used primarily for the treatment of neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal vascular diseases. This NDC corresponds to a 2-milligram preservative-free vial.
Market Overview
Market Size and Key Players
The global ophthalmology market focusing on anti-VEGF agents exceeds $12 billion in 2023, with Eylea occupying approximately 55% of the market share among prescribed anti-VEGF treatments in the United States. Several competitors exist, including:
- Ranibizumab (Lucentis)
- Bevacizumab (Off-label; Avastin)
- Faricimab (Vabysmo)
Eylea's distribution is widespread due to its favorable efficacy and dosing frequency.
Annual Sales and Market Penetration
According to IQVIA data, Eylea generated approximately $4.8 billion in U.S. sales in 2022. The annual growth rate for Eylea has averaged 3% over the past three years. This figure reflects strong physician preference, established efficacy, and dosing convenience (every 8 weeks after initial monthly doses).
Regulatory and Market Trends
- Patent protections for Eylea in the U.S. expire in 2023-2024, creating potential for generic or biosimilar competition.
- The FDA approved biosimilars, such as Mvasi (biosimilar for Avastin), but no biosimilar for Eylea has been approved as of 2023.
- Increased off-label use of cheaper alternatives, primarily compounded bevacizumab, pressures volume and pricing.
Price Projections
Current Pricing
Wholesale acquisition cost (WAC) for NDC 70677-0001 (2 mg prefilled vial):
- Approximate list price: $1,850 per vial.
- Reimbursement rates vary by insurer, with negotiated discounts reducing actual net costs.
Future Price Trends
- Patent Expiration Impact: The patent expiry in late 2023 to early 2024 is projected to introduce biosimilar competition, potentially reducing prices by 20-40% within two years of market entry.
- Biosimilar Penetration: Biosimilars typically retail at 20-30% discount compared to branded formulations. Initial discounts may reach 40% in competitive bidding environments.
- Market Dynamics: Increased use of biosimilars and potential biosimilar price could bring the average price for aflibercept to approximately $1,200-$1,400 per vial within 3-5 years.
- Reimbursement Trends: Managed care entities seek lower-cost alternatives, which could further pressure net prices.
Price Sensitivity and Market Volume
- Volume increases are constrained by the small target patient population (~1 million cases in the U.S.).
- Price reductions could incentivize increased patient access and higher volume prescriptions, partially offsetting revenue declines.
Competitive Pricing Landscape
| Product |
Approximate Price (per vial) |
Market Share (2023) |
Patent Status |
| Eylea (70677-0001) |
$1,850 |
55% |
Patent expiry imminent |
| Lucentis |
$2,200 |
20% |
Patent expired in 2018 |
| Avastin (off-label) |
$50 (compounded) |
15% |
Off-label use |
| Vabysmo |
$2,000 |
Emerging |
New biosimilar approved |
Risks and Opportunities
-
Opportunities
- Entry of biosimilars could significantly reduce costs.
- Digital health initiatives could improve adherence.
- Expansion into emerging markets presents growth prospects.
-
Risks
- Patent cliff leading to significant price erosion.
- Off-label use of cheaper alternatives impacting volume.
- Regulatory delays for biosimilar approvals.
Key Takeaways
- NDC 70677-0001 (Eylea) remains a high-margin product with established market dominance.
- Price reductions are anticipated, driven by patent expiration and biosimilar entries.
- The immediate future will likely see a price decline of 20-40% within two years.
- Market volume constraints imply revenue decline will be partly offset by increased patient access.
- Competition from off-label and biosimilar products remains a critical factor influencing pricing and market share.
FAQs
1. When will biosimilars for Eylea become available?
Biosimilar applications are under review or have been approved in various regions; U.S. FDA approval is anticipated in late 2023 or early 2024.
2. How much could prices decline with biosimilar entry?
Typically, biosimilar prices drop by 20-40% initially, with further reductions possible over time as market competition intensifies.
3. What is the key driver of Eylea’s market share?
Efficacy, dosing interval, and physician familiarity drive its dominant market position.
4. How does off-label use of bevacizumab impact Eylea’s sales?
Off-label use of bevacizumab at significantly lower costs can reduce the volume of Eylea prescriptions but remains limited by regulatory and reimbursement issues.
5. What are the main regulatory challenges ahead for Eylea?
Patent expirations and biosimilar approval processes represent primary regulatory hurdles influencing pricing and market dynamics.
References
- IQVIA. (2023). Ophthalmology Market Data.
- U.S. Food & Drug Administration. (2023). Biosimilar Development and Approval.
- EvaluatePharma. (2023). Oncology & Ophthalmology Market Outlook.
- FDA. (2022). Eylea (aflibercept) Prescribing Information.
- MarketsandMarkets. (2022). Ophthalmology Drugs Market Forecast.
